Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination With Atezolizumab in Subjects With Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

NCT03502785 is registered in ClinicalTrials.gov with Inovio Pharmaceuticals as lead sponsor.

NCT NCT03502785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03502785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination With Atezolizumab in Subjects With Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Lead sponsor
Inovio Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
July 24, 2018
Completion date
May 9, 2025
Enrollment
35 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma